natgillin/translations-raw huggingface dataset:
is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, cyano, C1-4alkyl, C1-4alkyloxy, C1-4alkylsulfonyl, perfluoroC1-4alkyl, perfluoroC1-4alkyloxy, diC1-4alkylamino, hydroxyl, and phenyl optionally substituted with 1, 2 or 3 substituents each independently selected from the group consisting of halo, C1-4alkyl and perfluoroC1-4alkyl; thienyl; thienyl substituted with 1 or 2 substituents each independently selected from the group consisting of halo and C1-4alkyl; naphthyl; pyridinyl; pyrrolyl; benzothiazolyl; indolyl; quinolinyl; C3-8cycloalkyl; or C5-7cycloalkenyl; 
R* je fenil; fenil supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, cijano, Cisalkil, Ciaalkiloksi, Ciaalkilsulfonil, perfluoroC,.alkil, perfluoroC,alkiloksi, diC,valkilamino, hidroksil, 1 fenil proizvoljno supstituiran sa 1, 2 ili 3 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo, Ciaalkil 1 perfluoroC,aalkil; tienil; tienil supstituiran sa 1 ili 2 supstituenta koji su svaki nezavisno odabrani iz skupine koja sadrži halo i C,aalkil; naftil; piridinil; pirolil; benzotiazolil; indolil; kinolinil; C3. sCikloalkil; ili Cs.gcikloalkenil;
The kit of claim 25, wherein the nebulizer operates by ultrasonic atomization, hydraulic atomization, or by a vibrating mesh. 
Komplet iz patentnog zahtjeva 25, pri čemu nebulizator radi uz pomoć ultrazvučne atomizacije, hidraulične atomizacije, ili uz pomoć vibrirajuće mrežice.
A pharmaceutical combination, containing a compound according to any one of claims 1-15, or a pharmaceutically acceptable salt thereof, and one or more therapeutic active substances, wherein said therapeutic active substance is selected from angiotensin II receptor antagonist or a pharmaceutically acceptable salt; HMG-Co-A reductase inhibitor or a pharmaceutically acceptable salt; calcium-channel blocker (CCB) or a pharmaceutically acceptable salt; dual angiotensin-convertion enzyme/neutral endopeptidase (ACE/NEP) inhibitor or a pharmaceutically acceptable salt; an antidiabetic drug; an antiobesic drug; aldosterone receptor block agent; endothelin receptor block agent; CETP inhibitor; Na-K-ATPase membrane pump inhibitor; B-adrenergic receptor inhibitor or a-adrenergic receptor blocking agent; neutral endopeptidase (NEP) inhibitor and inotropic agent. 
Farmaceutska kombinacija, koja sadrži spoj prema bilo kojem od zahtjeva 1-15, ili njegovu farmaceutski prihvatljivu sol, 1 jednu ili više terapeutski aktivnih tvari, pri čemu je spomenuta terapeutski aktivna tvar odabrana od antagonista angiotenzin II receptora ili farmaceutski prihvatljive soli; inhibitora HMG-Co-A reduktaze ili farmaceutski prihvatljive soli; blokatora kanala kalcija (CCB) ili farmaceutski prihvatljive soli; inhibitora dvostruke angiotenzin-pretvarajuće enzim/neutralne endopeptidaze (ACE/NEP) ili farmaceutski prihvatljive soli; antidijabetičkog lijeka; lijeka protiv gojaznosti; blokirajućeg agensa aldosteron receptora; blokirajućeg agensa endotelin receptora; CETP inhibitora; inhibitora Na-K-ATPaza membranske pumpe; inhibitora f-adrenergičnog receptora ili blokirajućeg agensa a-adrenergičnog receptora; inhibitora neutralne endopeptidaze (NEP) i inotropičnog agensa.
Such an embodiment may also be packed in an automated packing machine. 
Takvo ostvarenje može također biti pakirano u automatiziranom stroju za pakiranje.
A compound having the formula (I), or a pharmaceutically-acceptable salt, solvate, stereoisomer, and/or hydrate thereof, wherein: 
Spoj formule (I), [image] ili njegova farmaceutski prihvatljiva sol, solvat, stereoizomer i/ili hidrat, naznačen time što:
The method of claim 16 wherein the additional active agent is selected from formoterol, salmeterol, budesonide, and mometasone in free or pharmaceutically acceptable salt form. The method according to claim 17 wherein the additional active agent is formoterol fumarate in an amount of about 5-25 µg per daily metered nominal dose. The method according to claim 17 wherein the additional active agent is mometasone furoate in an amount of about 200-450 µg per daily metered nominal dose. 
Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 13, naznačen time, što je dodatna aktivna tvar odabrana iz formoterola, salmeterola, budezonida i flutikazon propionata, u slobodnom obliku ili u obliku farmaceutski prihvatljive soli. Aklidinij u slobodnom obliku ili u obliku farmaceutski prihvatljive soli za primjenu prema zahtjevu 14, naznačen time, što je (a) dodatna aktivna tvar formoterol fumarat u količini od 5-25 µg po dozi ili je (b) dodatna aktivna tvar formoterol fumarat u količini od 6 µg po dozi ili je (c) dodatna aktivna tvar formoterol fumarat u količini od 12 µg po dozi.
said cells express one or more additional markers selected in the group comprising alkaline phosphatase, SSEA-1, EMA-1, ENS-1. A process for producing a virus preparation, comprising the steps of: 
- < te stanice eksprimiraju jedan ili više dodatnih markera izabranih iz grupe koja obuhvaća alkalnu fosfatazu, SSEA-1, EMA-1, ENS-1,i gdje te stanice ne proizvode za replikaciju kompetentne endogene čestice retrovirusa.
In addition, the mixing member is shaped to uninterruptedly scrape the whole cylindrical inner surface of the bowl, to prevent the ingredient mixture inside the bowl from adhering to the lateral wall on account of the low temperature of the lateral wall. 
Uz to, članak za miješanje je oblikovan da neprekidno struže cijelu cilindričnu unutarnju plohu zdjele da spriječi da smjesa sastojaka unutar zdjele prione uz bočnu stijenku zbog niske temperature bočne stijenke.
The peptide according to any one of claims 1 to 3 for use in medicine. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, koji dodatno sadrži najmanje jednu stanicu koja predstavlja antigen.
The method of claim 1, wherein the final concentration for the at least one chaotrope is from 0.1 Molar to 2 Molar, the final concentration of the at least one kosmotrope is from 0.1 Molar to 2 Molar, the final concentration of the chelator is from 0.1 M to 2 Molar, and the final concentration of the apoptosis substrate is from 0.001 Molar to 0.5 Molar. 
Reagens prema zahtjevu 1, naznačen time da konačna koncentracija barem jednog kaotropa je od 0.1 Molarno do 2 Molarno, konačna koncentracija barem jednog kozmotropa je od 0.1 Molamo do 2 Molarno, konačna koncentracija kelatora je od 0.1 M do 2 Molarno, i konačna koncentracija supstrata apoptoze je od 0.001 Molarno do 0.5 Molarno.
The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is H. 
Spoj ili sol za upotrebu prema zahtjevu 1, pri čemu R2 je H.
The plates were incubated for 45 minutes and then the secondary antibody solution was removed from the wells followed by two 200 ul PBS/Tween 20 washes using a plate washer. 
Pločice se stave na inkubaciju od 45 minuta, i potom se otopina sekundarnog antitijela ukloni i pločice dvaput isperu sa 200 ul PBS / Tween 20 pomoću ispirača mikrotitarskih pločica.
Net-like rope assembly comprising at least two second ropes (2.2) and at least two ropes (2) comprising at least two swagings according to claim 10. 
Sklop mrežastog užeta koji sadrži najmanje dva druga užeta (2.2) i najmanje dva užeta (2) sadrže najmanje dva uprešana priključka prema bilo kojem od patentnih zahtjeva 15 do 17.
In another embodiment of this aspect, there is provided an oligonucleotide for use, wherein said oligonucleotide is repetitively administered as a single exposure on separate occasions 4 to 8 weeks apart. 
Oligonukleotid za primjenu prema patentnom zahtjevu 1, naznačen time, što se predmetni oligonukleotid opetovano primjenjuje u obliku jednokratne izloženosti u više navrata u razmaku od 4 do 8 tjedana.
Although AceK has a sweetness that is 200 times as high as sucrose, it appears to have a bitter and metallic aftertaste when used alone in foods and drinks. 
Premda je AceK 200 puta slađi od saharoze, nakon gutanja ostavlja gorak i metalni okus kada se koristi sam kao dodatak hrani ili piću.
The reaction was monitored by thin layer chromatography (TLC). 
Reakcija se prati tankoslojnom kromatografijom (TLC).
In addition, the present invention relates to the use of a compound of formula I in the manufacture of a medicament for treating or delaying the progression or onset of the diseases or disorders described herein in a human patient. 
Pored toga, ovaj izum se odnosi na primjenu spoja formule I u proizvodnji lijeka za liječenje ili odgađanje napredovanja ili početka bolesti ili poremećaja koji su ovdje opisani kod humanog pacijenta.
Use of a compound of formula (I) according to claim 1, or of a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the prevention or treatment of a disease selected from inflammatory diseases, obstructive airway diseases, allergic conditions, HIV-mediated retroviral infections, cardiovascular disorders, neuroinflammation, neurological disorders, pain, prion-mediated diseases and amyloid-mediated disorders; and for the modulation of immune responses. 
Uporaba spoja formule (1) prema zahtjevu 1 ili njegove farmaceutski prihvatljive soli, naznačena time, da je za proizvodnju lijeka za prevenciju ili liječenje bolesti odabrane od upalnih bolesti, opstrukcijskih bolesti dišnih putova, alergijskih stanja, retrovirusnih infekcija posredovanih HIV-om, kardiovaskularnih poremećaja, neurozapaljenja, neuroloških poremećaja, bolova, bolesti posredovanih prionom i poremećaja posredovanih amiloidom; i za modulaciju imunoloških reakcija.
a diuretic agent, the hormone or therapeutic peptide or protein, and 
diuretičkog sredstva, ili (viii) hormona ili terapijskog peptida ili proteina, ili
An aqueous preparation containing minerals and reuterin, wherein the aqueous preparation is an aqueous dispersion, suspension or slurry containing insoluble minerals in an aqueous medium and reuterin and has a solids content from 40 to 85 wt.-% of the total weight of the preparation. 
Vodeni pripravak koji sadrži minerale i reuterin, gdje je vodeni pripravak vodena disperzija, suspenzija ili mulj koji sadrži netopljive minerale u vodenom mediju i reuterin te ima sadržaj krutina od 40 do 85 wt-% od ukupne mase pripravka.
PTA-9017, wherein binding of said antibody to endosialin expressed on the surface of the endosialin-expressing cell inhibits the interaction of said endosialin-expressing cell with said collagen or fibronectin. 
što navedeno protutijelo ili antigenski vežući fragment inhibiraju međudjelovanje endosijalina eksprimiranog na površini stanice s kolagenom ili fibronektinom. 12.
The acyl group is preferably R1C(O)—, where R1 is substituted or unsubstituted C1-C24-alkyl, preferably C1-C10-alkyl, and more preferably C1-C6-alkyl; substituted or unsubstituted C2-C24-alkenyl, preferably C2-C10-alkenyl, and more preferably C2-C6-alkenyl; substituted or unsubstituted C2-C24-alkynyl, preferably C2-C10-alkynyl, and more preferably C2-C6-alkynyl; substituted or unsubstituted aryl, preferably substituted or unsubstituted phenyl; or substituted or unsubstituted heteroaryl. 
Spoj prema zahtjevu 1 naznačen time da R je RiC(O)-, naznačen time da R, je supstituirani ili nesupstituirani C,- Cx-alkil; supstituirani ili nesupstituirani C,>-C24-alkenil; supstituirani ili nesupstituirani C>-C,-alkinil; supstituirani ili nesupstituirani aril; ili supstituirani ili nesupstituirani heteroaril. Spoj prema zahtjevu 2 naznačen time da R, je supstituirani ili nesupstituirani C;-Cy-alkil ili supstituirani ili nesupstituirani C2-Cg alkenil. Spoj prema zahtjevu 1 naznačen time da R je H ili acetil.
thereafter separating the first movable contact from the first fixed contact and is contacted by the second fixed contact. 
prvi pokretni kontakt (6) odvojen je od prvog fiksnog kontakta (4) i u kontaktu je s drugim fiksnim kontaktom (5).
In an embodiment, the alcohol phase comprises a content of an alcohol, such as a lower alcohol in an amount so that the content of the lower-alcohol phase relative to the total amount of the alcohol-in-oil type emulsion is in the range of 45-95% (w/w), 55-85% (w/w), such as 65-75% (w/w). 
Emulzija tipa alkohol-u-ulju u skladu s bilo kojim od patentnih zahtjeva 1 do 4, gdje sadržaj niže alkoholne faze u odnosu na ukupnu količinu emulzije tipa alkohol-u-ulju je u rasponu od 45 do 95 % (težinski), 55 do 85 % (težinski), primjerice 65 do 75 % (težinski).
Process for the synthesis 7,8-dimethoxy-1,3-dihydro-benzazepin-2-one of formula (II) from 3,4-dimethoxy-phenylacetic acid of formula (III) characterized by 
Postupak za sintezu 7,8-dimetoksi-1,3-dihidro-benzazepin-2-ona formule (II) iz 3,4-dimetoksi-fenil-octene kiseline formule (III) naznačen i)
Ulipristal acetate or a metabolite thereof selected from the group consisting of CDB-3877, CDB-3963, CDB-3236, and CDB-4183 for use in treating metastatic leiomyoma in a patient. 
Ulipristal acetat, 1li bilo koji metabolit izabran iz grupe koja obuhvaća CDB-3877, CDB-3963, CDB-3236, i CDB- 4183, za uporabu radi smanjenja ili zaustavljanja krvarenja u bolesnice koja boluje od uterinih fibroida prema zahtjevu 1 pri čemu ulipristal acetat ili metabolit dalje djeluje kao kontraceptiv.
Machinery according to one of claims 5 to 8, characterised in that it is of the autonomous type and can be fed with flat electro-welded metal nets, pre-built for this purpose, which are distributed by a special movable automatic magazine that is provided with trolleys (52) for carrying electro-welded metal nets of various sizes and/or geometric shapes. 
Stroj prema jednom zahtjevu od 5 do 8, naznačen time da je autonomnog tipa i može se puniti sa ravnim elektrozavarenim metalnim mrežama, prethodno proizvedenim za ovu svrhu, koje se distribuiraju pomoću posebnog pomičnog automatskog spremnika opremljenog sa kolicima (52) za prenošenje elektro-zavarenih metalnih mreža različitih veličina i/ili geometrijskih oblika.
Pharmaceutical composition comprising the adult stem cells obtained according to the method as defined in any claim from 1 to 8 at a concentration comprised between 90-250x103 cells/ml, preferably 100-120x103 cells/ml, as active principle, together with pharmacologically acceptable adjuvants and/or excipients, said composition being formulated for intravenous injection, for use in the treatment of lesions chosen from the group consisting of cutaneous lesions, lesions to the tendons, to the ligaments, to the bones, to the mucous membranes in mammals, or fractures, of neurological or neurodegenerative pathologies chosen from the group consisting of Cushing's disease, head shaking, Wobbler's syndrome, breathing difficulties, paresis of the limbs in mammals, of acute or chronic inflammatory pathologies chosen from laminitis, periostitis, gastritis, arthrosis, inflammations caused by viral, bacterial, parasite, mycotic agents in mammals, of the syndrome of dilatation-torsion of the stomach in mammals. 
Farmaceutski pripravak koji sadrži odrasle matične stanice dobivene prema metodi kao što je definirano u bilo kojem od patentnih zahtjeva 1 do 8 u koncentraciji sadržanoj između 90-250x10* stanica/mL, kao aktivnu tvar, zajedno sa farmakološki prihvatljivim adjuvansima i/ili ekscipijensima, pri čemu se spomenuti pripravak formulira za intravenoznu injekciju, za uporabu u liječenju lezija izabranih iz skupine koja sadrži kožne lezije, lezije tetiva, ligamenata, kostiju, mukozne membrane u sisavcima, ili fraktura, neuroloških ili neurodegenerativnih patologija izabranih iz skupine koja se sastoji od Cushingove bolesti, trešnje glave, Wobblerovog sindroma, teškoća s disanjem, pareze udova u sisavcima, akutnih i kroničnih upalnih patologija izabranih iz laminitisa, periostitisa, gastritisa, artroze, upala uzrokovanih virusnim, bakterijskim, parazitskim, mikotskim agensima u sisavcima, sindroma dilatacije-torzije želuca u sisavcima.
The method according to claim 1, where chromosome of interest is chromosome 8, 9, 13, 16, 18, 21, 22 and X. 
Postupak sukladno patentnom zahtjevu 1, pri čemu kromosom od interesa je kromosom 8, 9, 13, 16, 18, 21, 221 X.
The composition of claim 1, wherein the composition has a loss factor of tan δ<0.3 in a temperature range from room temperature to approximately 200° C., said loss factor being a ratio of loss to storage modulus under dynamic shear stress. 
Mješavina u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što mješavina u rasponu temperatura od sobne temperature do otprilike 200 °C ima faktor gubitka (odnos između modula gubitka i modula spremanja uz naprezanje dinamičnog smicanja) od tan δ
• a signal is generated by a detector of said flammable gas release, or by an operator, or by an approaching flame or by the explosion itself, or by any combination thereof, 
. pomoću detektora bude izazvan signal oslobađanja zapaljivog plina ili operatera ili preko približavjućeg požara ili preko same eksplozije ili bilo koje njihove kombinacije,
The IL-17 binding antibody or fragment thereof for use according to any of the preceding claims, wherein said IL-17 binding antibody or fragment thereof is to be co-administered, concomitantly or in sequence, with at least one second drug substance selected from the group consisting of immunosuppressive agents, immunomodulatory agents, anti-inflammatory agents, chemotherapeutic agents or anti-infectious agents. 
Uporaba IL-17-vezivnog protutijela ili njegovog fragmenta koji obuhvaćaju varijabilne domene kako teškog lanca (VH) tako i lakog lanca (VL), naznačena time, da je za proizvodnju lijeka za liječenje ankiloznog spondilitisa, pri čemu spomenuto IL-17-vezivno protutijelo ili njegov fragment sadrži najmanje jedno mjesto za vezanje antigena, koje obuhvaća sljedeće:
The term “aryl” refers to aromatic hydrocarbon rings such as phenyl or naphthyl. 
Pojam "aril" odnosi se na ugljikovodike sa aromatskim prstenom, poput fenila ili naftila.
A method according to claim 2, wherein the speed of the pressing assembly in the direction of travel of the board is matched to the speed of the board using a Hoekens linkage. 
Postupak prema zahtjevu 9, naznačen time da je brzina pritisnog sklopa (10) u smjeru pomicanja ploče (100) usklađena s brzinom ploče pomoću Hoekensovog povezivanja.
benzofuran compounds: from 0.2 to 25 mg; and possibly 
benzofuranski spojevi: od 0.2 do 25 mg, a može biti
wherein ring U represents aryl or heteroaryl; 
(ia) gdje prsten U predstavlja aril ili heteroaril;
Another aspect of the present invention pertains to uses of the compounds of Formula (I), as described herein, for the manufacture of a medicament for use in the treatment of a metabolic-related disorder. 
Slijedeći aspekt prikazanog izuma odnosi se na uporabu spojeva Formule (I), kako je već ovdje opisana, za izradu lijeka za uporabu u liječenju metabolički pripadajućih poremećaja.
or a polymer selected from the group consisting of polyalkylene glycols, and polyalkylene oxides. 
ili polimer odabran iz skupine koju čine polimeri ionskog akrilnog polimera, polialkilen glikoli, polialkilen oksidi, celuloze i derivati celuloze.
The method of claim 9, wherein treatment with a dose of at least 1.5 g/day metformin and of at least 10 units/day of insulin alone for three months does not adequately control diabetes mellitus type 2. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 7, naznačena time što liječenje samo dozom od najmanje 1,5 g dnevno metformina i najmanje 10 jedinica dnevno inzulina tijekom tri mjeseca nije dovoljna kontrola za dijabetes melitus tip 2.
a plunger rod (60) arranged within said distal housing; 
klipnu šipku (60) smještenu unutar navedenog distalnog kućišta;
Conveyor means according to claim 1, wherein the conveyor means further comprises a guide means (241) adapted to secure a returnable item deposited in the radially extending recess as the drum is positioned in a rotational position between the second rotational position and the first output or a second output. 
Prema gore orijentirano skladište prema patentnom zahtjevu 13 ili 14, naznačeno time, što transportno sredstvo dalje sadrži sredstvo (241) za vođenje prilagođeno da zadrži povratni predmet koji se nalazi u udubljenju dok je bubanj postavljen u rotacijski položaj između drugog rotacijskog položaja i prvog izlaza ili drugog izlaza.
The upper inner element 16 is adapted to store an optical element by means of engaging means 18. 
Gornji unutarnji element 16 je prilagođen da pohrani optički element kojega zahvaća sredstvo za zahvaćanje 18.
In principle, the second embodiment corresponds to the above-described process, however, in the second embodiment, waste boards ("backing boards") from oak (solid wood) having a thickness of 13 mm with an amount of a humidity of approximately 65 % which result from the manufacture of veneers were provided without an extended storing period for the manufacture of a block of wood according to the invention. 
U principu, drugo ostvarenje odgovara gore opisanom postupku, međutim, u drugom ostvarenju, otpadne ploče ("potporne ploče") od hrasta (puno drvo) koje imaju debljinu od 13 mm s veličinom vlažnosti od približno 65 %, što rezultira od proizvodnje furnira, jer su bile dobavljene bez produženog razdoblje skladištenja za proizvodnju blokova od drva.
The antibody or antibody fragment of claim 6, wherein said antibody is of the IgG isotype. 
Antitijelo ili fragment antitijela specifičan za IL17C za uporabu iz patentnog zahtjeva 3, naznačen time, što je navedeno antitijelo IgG izotipa.
The mechanism of hydrophobic adsorption is not well understood, and several theories exist to explain the process, all of which have at their core the increased structure of water molecules surrounding the protein-ligand complex (Amersham Biosciences 1993). 
Mehanizam hidrofobnie adsorpcije je jedovoljni istražen, te postoji nekoliko teorija kojima se nastoji objasniti ovaj proces, kojima je zajednička povećana struktura vode koja okružuje kompleks protcin-ligand (Amcrsham Bioscicnecs 1993).
In a first aspect, the present invention is directed to an antibody that binds human receptor tyrosine kinase FLT3, wherein said antibody comprises a heavy chain and/or a light chain and has at least one amino acid substitution in the constant region relative to a parent anti-FLT3 antibody, wherein said at least one amino acid substitution includes the amino acid substitutions 239D and 332E, wherein the positional numbering is according to the EU index (Kabat et al., 1983). 
HR P20160422 T1 PATENTNI ZAHTJEVI IgG protutijelo koje se veže na ljudsku receptorsku tirozinsku kinazu FILLT3, naznačeno time što navedeno protutijelo sadrži teški lanac i laki lanac, te aminokiselinu zamjenu u konstantnom području u odnosu na osnovno protutijelo protiv FLT3, gdje se navedena aminokiselina zamjena sastoji u aminokiselinskim zamjenama S239D i 1332E, gdje je pozicijsko numeriranje izvršeno u skladu s EU indeksom.
The addition of urea involves, however, a considerable complication in the preparatory step, in as much as the urea has to be dissolved in the resin dispersion immediately before use; the dispersion itself must be heated in order to avoid precipitation due to the cooling caused by the urea dissolution and furthermore because there must be provided a control and correction of the pH which may turn out to heve changed because of the addition of urea or other blocking agents. 
Dodatak urina prouzrokuje popriličnu komplikaciju u stupnju pripreme, jer treba urin rastopiti u disperziji smole neposredno prije upotrebe; disperziju samu potrebno je zagrijavati, da izbjegnemo taloženje zbog hlađenja, kojeg prouzrokuje rastapanje urina, pored toga potrebno se je pobrinuti za kontrolu i korekciju pH. pH se naime može promijeniti zbog dodatka urina ili drugih sredstava za blokiranje. HR P940799 B1 Opis rješenja tehničkog problema sa izvedbenim primjerima
Embodiment 2. The method of embodiment 1, wherein the mammal is a human being that receives a total monthly dose of zoledronic acid that is about 30 mg/m2 to about 700 mg/m2. 
Zoledronska kiselina, namijenjena upotrebi u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačena time što je sisavac ljudsko biće, a ukupna mjesečna doza zoledronske kiseline je 100 mg/m* do 200 mg/m".